Allergan (AGN) Offering Possible 22.25% Return Over the Next 15 Calendar Days

This article was originally published on this site

Allergan’s most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $205.00 short put and a strike $200.00 long put offers a potential 22.25% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $205.00 by expiration. The full premium credit of $0.91 would be kept by the premium seller. The risk of $4.09 would be incurred if the stock dropped below the $200.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.

The RSI indicator is at 33.62 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Allergan

U.S. House committee launches probe of Allergan patent deal
Tue, 03 Oct 2017 20:43:24 +0000
A U.S. House of Representatives committee launched a probe into drugmaker Allergan Plc’s (AGN.N) deal to transfer some of its patents to a Native American tribe to shield them from review. Allergan said last month that it was transferring patents on its dry eye medication Restasis to New York’s Saint Regis Mohawk Tribe, which agreed to exclusively license them back to the company in exchange for ongoing payments.

Drugmaker Under Fire For Using Mohawk Tribe To Shield Patent
Tue, 03 Oct 2017 20:27:04 +0000
What’s got a tax address in Ireland, a blockbuster drug on a Native American reservation, and new trouble in Washington?

Allergan’s unusual patent agreement
Tue, 03 Oct 2017 19:45:00 +0000
CNBC’s Meg Tirrell reports on senators commenting on Allergan’s patent agreement with the Saint Regis Mohawk Tribe.

Allergan Patent Deal May Hurt Competition, Lawmakers Say
Tue, 03 Oct 2017 17:23:57 +0000
What’s got a tax address in Ireland, headquarters in New Jersey, a blockbuster drug on a Native American reservation, and new trouble in Washington?

Allergan CEO says patent review flawed in response to senators
Tue, 03 Oct 2017 16:53:09 +0000
Allergan Plc (AGN.N) Chief Executive Brent Saunders on Tuesday defended his company’s decision to transfer drug patents to a Native American tribe as a proper way to shield them from a flawed patent review process, in a response to congressional criticism. Saunders sent a letter to Republican Senator Charles Grassley and Democratic Senator Dianne Feinstein, the chairman and ranking member of the Senate Judiciary Committee, after four Democratic U.S. senators asked them to launch a committee investigation into the deal.

Be Sociable, Share!

Related Posts